Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency
Disease Models & Mechanisms · 01.06.2023 · 16 (6)
DOI: 10.1242/dmm.049954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 10.05.2023. Verfasst von Marcus Keatinge und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bateson Centre, Firth Court, University of Sheffield, Western Bank, Sheffield S10 2TN, UK. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type A, Parkinson Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parkinson's UK, Medical Research Council, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Heterozygous variants in GBA1, encoding glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's disease (PD). Moreover, sporadic PD patients also have a substantial reduction of GCase activity. Genetic variants of SMPD1 are also overrepresented in PD cohorts, whereas a reduction of its encoded enzyme (acid sphingomyelinase or ASM) activity is linked to an earlier age of PD onset. Despite both converging on the ceramide pathway, how the combined deficiencies of both enzymes might interact to modulate PD has yet to be explored. Therefore, we created a double-knockout (DKO) zebrafish line for both gba1 (or gba) and smpd1 to test for an interaction in vivo, hypothesising an exacerbation of phenotypes in the DKO line compared to those for single mutants. Unexpectedly, DKO zebrafish maintained conventional swimming behaviour and had normalised neuronal gene expression signatures compared to those of single mutants. We further identified rescue of mitochondrial Complexes I and IV in DKO zebrafish. Despite having an unexpected rescue effect, our results confirm ASM as a modifier of GBA1 deficiency in vivo. Our study highlights the need for validating how genetic variants and enzymatic deficiencies may interact in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bateson Centre, Firth Court, University of Sheffield, Western Bank, Sheffield S10 2TN, UK.
- Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, UK.
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh EH16 4TJ, UK.
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
- Eli Lilly and Company, Drop Code 1940, Indianapolis, IN 46285, USA.
- Department of Laboratory Medicine, Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen NL-6525 GA, The Netherlands.
ORCID-Profile: Marcus Keatinge, Ryan B MacDonald, Oliver Bandmann
Förderung
- Parkinson's UK
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
- NIHR Sheffield Biomedical Research Centre
- University College London
- Niemann-Pick UK
Zitieren
APA
Keatinge, M., Gegg, M. E., Watson, L., Mortiboys, H., Li, N., Dunning, M., Ailani, D., Bui, H., van Rens, A., Lefeber, D. J., Schapira, A. H. V., MacDonald, R. B., & Bandmann, O. (2023). Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency. Disease Models & Mechanisms, 16(6). https://doi.org/10.1242/dmm.049954
Vancouver
Keatinge M, Gegg ME, Watson L, Mortiboys H, Li N, Dunning M, et al. Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency. Disease Models & Mechanisms. 2023;16(6). doi:10.1242/dmm.049954
BibTeX
@article{Keatinge2023,
author = {Keatinge, Marcus and Gegg, Matthew E and Watson, Lisa and Mortiboys, Heather and Li, Nan and Dunning, Mark and Ailani, Deepak and Bui, Hai and van Rens, Astrid and Lefeber, Dirk J and Schapira, Anthony H V and MacDonald, Ryan B and Bandmann, Oliver},
title = {Unexpected phenotypic and molecular changes of combined glucocerebrosidase and acid sphingomyelinase deficiency},
journal = {Disease Models & Mechanisms},
year = {2023},
volume = {16},
number = {6},
doi = {10.1242/dmm.049954}
}
EUVIMED